Mitochondrial transplantation in myocardial ischemia and reperfusion injury

68Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Ischemic heart disease remains the leading cause of death worldwide. Mitochondria are the power plant of the cardiomyocyte, generating more than 95% of the cardiac ATP. Complex cellular responses to myocardial ischemia converge on mitochondrial malfunction which persists and increases after reperfusion, determining the extent of cellular viability and post-ischemic functional recovery. In a quest to ameliorate various points in pathways from mitochondrial damage to myocardial necrosis, exhaustive pharmacologic and genetic tools have targeted various mediators of ischemia and reperfusion injury and procedural techniques without applicable success. The new concept of replacing damaged mitochondria with healthy mitochondria at the onset of reperfusion by auto-transplantation is emerging not only as potential therapy of myocardial rescue, but as gateway to a deeper understanding of mitochondrial metabolism and function. In this chapter, we explore the mechanisms of mitochondrial dysfunction during ischemia and reperfusion, current developments in the methodology of mitochondrial transplantation, mechanisms of cardioprotection and their clinical implications.

Cite

CITATION STYLE

APA

Shin, B., Cowan, D. B., Emani, S. M., del Nido, P. J., & McCully, J. D. (2017). Mitochondrial transplantation in myocardial ischemia and reperfusion injury. In Advances in Experimental Medicine and Biology (Vol. 982, pp. 595–619). Springer New York LLC. https://doi.org/10.1007/978-3-319-55330-6_31

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free